Header Logo

Connection

Johnny Mahlangu to Factor VIII

Back to Details
This is a "connection" page, showing publications Johnny Mahlangu has written about Factor VIII.
Johnny Mahlangu
Connection Strength
12,164
Factor VIII
  1. Extension Study With rVIII-SingleChain in Previously Untreated Patients (PUPs) With Severe Haemophilia A. Haemophilia. 2025 Mar; 31(2):214-223.
    View in: PubMed
    Score: 0,912
  2. Emicizumab and unmet needs of patients with hemophilia a who are managed with replacement therapies. Expert Rev Hematol. 2024 Oct; 17(10):741-748.
    View in: PubMed
    Score: 0,887
  3. Three-year outcomes of valoctocogene roxaparvovec gene therapy for hemophilia A. J Thromb Haemost. 2024 Jul; 22(7):1880-1893.
    View in: PubMed
    Score: 0,862
  4. Two-Year Outcomes of Valoctocogene Roxaparvovec Therapy for Hemophilia A. N Engl J Med. 2023 02 23; 388(8):694-705.
    View in: PubMed
    Score: 0,796
  5. BAY 81-8973 demonstrated efficacy, safety and joint status improvement in patients with severe haemophilia A in the LEOPOLD I extension for =2 years. Eur J Haematol. 2020 Jun; 104(6):594-601.
    View in: PubMed
    Score: 0,650
  6. Bleeding and safety outcomes in persons with haemophilia A without inhibitors: Results from a prospective non-interventional study in a real-world setting. Haemophilia. 2019 Mar; 25(2):213-220.
    View in: PubMed
    Score: 0,602
  7. rFVIIIFC for hemophilia A prophylaxis. Expert Rev Hematol. 2018 12; 11(12):937-943.
    View in: PubMed
    Score: 0,594
  8. Bleeding events and safety outcomes in persons with haemophilia A with inhibitors: A prospective, multi-centre, non-interventional study. Haemophilia. 2018 Nov; 24(6):921-929.
    View in: PubMed
    Score: 0,588
  9. Defining extended half-life rFVIII-A critical review of the evidence. Haemophilia. 2018 May; 24(3):348-358.
    View in: PubMed
    Score: 0,568
  10. Extended half-life clotting factor concentrates: results from published clinical trials. Haemophilia. 2016 Jul; 22 Suppl 5:25-30.
    View in: PubMed
    Score: 0,502
  11. Efficacy and safety of rVIII-SingleChain: results of a phase 1/3 multicenter clinical trial in severe hemophilia A. Blood. 2016 08 04; 128(5):630-7.
    View in: PubMed
    Score: 0,501
  12. Long-acting recombinant factor VIII Fc fusion protein (rFVIIIFc) for perioperative haemostatic management in severe haemophilia A. Thromb Haemost. 2016 07 04; 116(1):1-8.
    View in: PubMed
    Score: 0,492
  13. Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A. Blood. 2014 Jan 16; 123(3):317-25.
    View in: PubMed
    Score: 0,419
  14. Emicizumab state-of-the-art update. Haemophilia. 2022 May; 28 Suppl 4:103-110.
    View in: PubMed
    Score: 0,188
  15. An update of the current pharmacotherapeutic armamentarium for hemophilia A. Expert Opin Pharmacother. 2022 Jan; 23(1):129-138.
    View in: PubMed
    Score: 0,179
  16. Development and testing of the Satisfaction Questionnaire with Intravenous or Subcutaneous Hemophilia Injection and results from the Phase 3 HAVEN 3 study of emicizumab prophylaxis in persons with haemophilia A without FVIII inhibitors. Haemophilia. 2021 Mar; 27(2):221-228.
    View in: PubMed
    Score: 0,173
  17. The changing treatment landscape in haemophilia: from standard half-life clotting factor concentrates to gene editing. Lancet. 2021 02 13; 397(10274):630-640.
    View in: PubMed
    Score: 0,172
  18. Health-related quality of life and caregiver burden of emicizumab in children with haemophilia A and factor VIII inhibitors-Results from the HAVEN 2 study. Haemophilia. 2020 Nov; 26(6):1009-1018.
    View in: PubMed
    Score: 0,169
  19. Outcomes in children with hemophilia A with inhibitors: Results from a noninterventional study. Pediatr Blood Cancer. 2020 10; 67(10):e28474.
    View in: PubMed
    Score: 0,167
  20. Redefining prophylaxis in the modern era. Haemophilia. 2021 Feb; 27 Suppl 3:21-27.
    View in: PubMed
    Score: 0,165
  21. Recombinant factor VIII Fc fusion protein for the treatment of severe haemophilia A: Final results from the ASPIRE extension study. Haemophilia. 2020 May; 26(3):494-502.
    View in: PubMed
    Score: 0,163
  22. Bispecific Antibody Emicizumab for Haemophilia A: A Breakthrough for Patients with Inhibitors. BioDrugs. 2018 Dec; 32(6):561-570.
    View in: PubMed
    Score: 0,149
  23. The predictive value of factor VIII/factor IX levels to define the severity of hemophilia: communication from the SSC of ISTH. J Thromb Haemost. 2018 10; 16(10):2106-2110.
    View in: PubMed
    Score: 0,146
  24. Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors. N Engl J Med. 2018 08 30; 379(9):811-822.
    View in: PubMed
    Score: 0,146
  25. Pharmacokinetic modelling and validation of the half-life extension needed to reduce the burden of infusions compared with standard factor VIII. Haemophilia. 2018 May; 24(3):376-384.
    View in: PubMed
    Score: 0,143
  26. Improved joint health in subjects with severe haemophilia A treated prophylactically with recombinant factor VIII Fc fusion protein. Haemophilia. 2018 Jan; 24(1):77-84.
    View in: PubMed
    Score: 0,138
  27. Treatment of bleeding episodes with recombinant factor VIII Fc fusion protein in A-LONG study subjects with severe haemophilia A. Haemophilia. 2017 May; 23(3):392-399.
    View in: PubMed
    Score: 0,131
  28. Recombinant B-domain-deleted porcine sequence factor VIII (r-pFVIII) for the treatment of bleeding in patients with congenital haemophilia A and inhibitors. Haemophilia. 2017 Jan; 23(1):33-41.
    View in: PubMed
    Score: 0,128
  29. A Randomized Trial of Factor VIII and Neutralizing Antibodies in Hemophilia A. N Engl J Med. 2016 May 26; 374(21):2054-64.
    View in: PubMed
    Score: 0,125
  30. Long-term safety and efficacy of recombinant factor VIII Fc fusion protein (rFVIIIFc) in subjects with haemophilia A. Haemophilia. 2016 Jan; 22(1):72-80.
    View in: PubMed
    Score: 0,118
  31. Recombinant factor VIII Fc fusion protein for the prevention and treatment of bleeding in children with severe hemophilia A. J Thromb Haemost. 2015 Jun; 13(6):967-77.
    View in: PubMed
    Score: 0,116
  32. Recombinant factor VIII Fc fusion protein: extended-interval dosing maintains low bleeding rates and correlates with von Willebrand factor levels. J Thromb Haemost. 2014 Nov; 12(11):1788-800.
    View in: PubMed
    Score: 0,111
  33. Genetic factors influencing inhibitor development in a cohort of South African haemophilia A patients. Haemophilia. 2014 Sep; 20(5):687-92.
    View in: PubMed
    Score: 0,109
  34. Key issues in inhibitor management in patients with haemophilia. Blood Transfus. 2014 Jan; 12 Suppl 1:s319-29.
    View in: PubMed
    Score: 0,105
  35. Haemophilia management: time to get personal? Haemophilia. 2011 Sep; 17(5):721-8.
    View in: PubMed
    Score: 0,088
  36. Haemophilia care in South Africa: 2004-2007 look back. Haemophilia. 2009 Jan; 15(1):135-41.
    View in: PubMed
    Score: 0,073
  37. RNA sequencing suggests that non-coding RNAs play a role in the development of acquired haemophilia. J Cell Mol Med. 2023 07; 27(13):1790-1796.
    View in: PubMed
    Score: 0,051
  38. Reclassifying hemophilia to include the definition of outcomes and phenotype as new targets. J Thromb Haemost. 2023 07; 21(7):1737-1740.
    View in: PubMed
    Score: 0,050
  39. Emicizumab in people with moderate or mild haemophilia A (HAVEN 6): a multicentre, open-label, single-arm, phase 3 study. Lancet Haematol. 2023 Mar; 10(3):e168-e177.
    View in: PubMed
    Score: 0,050
  40. Valoctocogene Roxaparvovec Gene Therapy for Hemophilia A. N Engl J Med. 2022 03 17; 386(11):1013-1025.
    View in: PubMed
    Score: 0,047
  41. Patient preference for emicizumab versus prior factor therapy in people with haemophilia A: Results from the HAVEN 3 and HAVEN 4 studies. Haemophilia. 2021 Nov; 27(6):e772-e775.
    View in: PubMed
    Score: 0,045
  42. A new hemophilia carrier nomenclature to define hemophilia in women and girls: Communication from the SSC of the ISTH. J Thromb Haemost. 2021 08; 19(8):1883-1887.
    View in: PubMed
    Score: 0,045
  43. The effect of emicizumab prophylaxis on long-term, self-reported physical health in persons with haemophilia A without factor VIII inhibitors in the HAVEN 3 and HAVEN 4 studies. Haemophilia. 2021 Sep; 27(5):854-865.
    View in: PubMed
    Score: 0,044
  44. Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies. Blood. 2021 04 22; 137(16):2231-2242.
    View in: PubMed
    Score: 0,044
  45. Health-related quality of life and health status in adolescent and adult people with haemophilia A without factor VIII inhibitors-A non-interventional study. Haemophilia. 2021 May; 27(3):398-407.
    View in: PubMed
    Score: 0,043
  46. Application of a hemophilia mortality framework to the Emicizumab Global Safety Database. J Thromb Haemost. 2021 01; 19 Suppl 1:32-41.
    View in: PubMed
    Score: 0,043
  47. A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors. Blood. 2019 12 12; 134(24):2127-2138.
    View in: PubMed
    Score: 0,040
  48. The effect of emicizumab prophylaxis on health-related outcomes in persons with haemophilia A with inhibitors: HAVEN 1 Study. Haemophilia. 2019 Jan; 25(1):33-44.
    View in: PubMed
    Score: 0,037
  49. Emicizumab Prophylaxis in Hemophilia A with Inhibitors. N Engl J Med. 2017 08 31; 377(9):809-818.
    View in: PubMed
    Score: 0,034
  50. Genotype-phenotype correlation in combined deficiency of factor V and factor VIII. Blood. 2008 Jun 15; 111(12):5592-600.
    View in: PubMed
    Score: 0,018
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.